Multiple myeloma, version 1.2013: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 1, 2013, Pages 11-17

  Anderson, Kenneth C ^a   Alsina, Melissa ^b   Bensinger, William ^c   Biermann, J Sybil ^d   Cohen, Adam D ^e   Devine, Steven ^f   Djulbegovic, Benjamin ^b   Faber, Edward A ^g   Gasparetto, Cristina ^h   Hernandez Illizaliturri, Francisco ⁱ   Huff, Carol Ann ^j   Kassim, Adetola ^k   Krishnan, Amrita Y ^l   Liedtke, Michael ^m   Meredith, Ruby ⁿ   Raje, Noopur ^o   Schriber, Jeffrey ^p   Singhal, Seema ^q   Somlo, George ^l   Stockerl Goldstein, Keith ^r   Treon, Steven P ^a   Weber, Donna ^p   Yahalom, Joachim ^s   Yunus, Furhan ^t   Shead, Dorothy A ^u   Kumar, Rashmi ^u   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g NEBRASKA MEDICAL CENTER   (United States)

^h DUKE CANCER INSTITUTE   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k VANDERBILT INGRAM CANCER CENTER   (United States)

^l CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^m STANFORD CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r BARNES JEWISH HOSPITAL   (United States)

^s MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^t ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^u National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; THALIDOMIDE; VINCA ALKALOID; VORINOSTAT;

ACCREDITATION; ALGORITHM; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DESTRUCTION; BONE MARROW DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; INCIDENCE; LOW DRUG DOSE; MEDICAL LITERATURE; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RELAPSE; SALVAGE THERAPY; THROMBOCYTOPENIA;

EID: 84874630363     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0004     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Siegel DS, Martin T, Singhal S, et al. Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1 [abstract]. J Clin Oncol 2012;30:Abstract 8035.
3. Berenson JR, Yellin O, Dichmann R, et al. A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen [abstract]. J Clin Oncol 2012;30:Abstract 8098.
4. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011;17:2734-2743.
5. Kirk CJ, Jiang J, Muchamuel T, et al. The selective proteasome inhibitor carfilzomib is well tolerated in experimental animals with dose intensive administration [abstract]. Blood 2008;112:Abstract 2765.
6. Siegel DS, Martin T, Wang M, et al. A phase 2 study of singleagent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817-2825.
7. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-440.
8. Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized, phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012;97:1925-1928.
9. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib or highdose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
10. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
11. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomibnaive patients with relapsed and/or refractory multiple myeloma. Blood 2012;119:5661-5670.
12. Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012;158:739-748.
13. Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012;30:2475-2482.
14. Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119:4608-4613.
15. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15:5250-5257.
16. Siegel DS, Dimopoulos MA, Yoon SS, et al. Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial [abstract]. Blood 2011;118:Abstract 480.
17. Dimopoulos MA, Jagannath S, Yoon SS, et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial [abstract]. Blood 2011;118:Abstract 811.
18. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012;26:595-608.
19. Richardson PG, Laubach JP, Schlossman RL, et al. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw 2010;8(Suppl 1):S4-12.
20. Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan- prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 2011;86:23-31.